Annula Genernal Meeting Date Change:  Klaria Pharma Holding (publ)

Due to the change of auditor in Klaria Holding AB, the board has decided to move the date of the annual general meeting to 26 May 2026 at 10:00 and the publication of the 2025 annual report to 5 May 2026.

The reason for the change of auditor from BDO Sweden to Azets Revision och Rådgivning AB was to avoid a conflict of interest with the business development assignment that BDO LLP’s UK Life Sciences M&A is performing together with Klaria. To give Azets the opportunity to carry out the audit without excessive time pressure, the board has decided to change the date of the 2025 annual general meeting.

Board of Directors

Klaria Pharma Holding

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.

For more information, visit the  Klaria Pharma Holding website klaria.com or contact:
info@klaria.com
Tel: +46 (0) 8-446 42 99

Läs mer på Cision